With no routine screening test currently available, ovarian cancer remains one of the deadliest cancers for patients globally. In Newfoundland and Labrador, the frequency of certain risk variants is over 50 times higher than in other populations, suggesting the potential to identify other genetic drivers of disease onset and progression that may be missed elsewhere.

Like other health research, there is no guarantee this study will result in any significant breakthroughs or directy benefit participants or their families. By taking part in this study, you are contributing to scientific research which may eventually lead to meaningful changes in clinical care.

Questions about your rights as a participant in a research study? Contact the HREA Ethics Office. They are not involved with running this study. Call 709-864-8871 or email info@hrea.ca.